Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Trial details
- Registry ID
- NCT07011719
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as AB521
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaNCT07011719 | RCUS | Phase 3 | Recruiting | 2028-04Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |